Gilead Sciences Inc. (GILD)
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Gilead Sciences (GILD) Surpasses Market Returns: Some Facts Worth Knowing
In the most recent trading session, Gilead Sciences (GILD) closed at $122.59, indicating a +1.23% shift from the previous trading day.
Gilead Sciences: From All-Time Highs To Higher Highs
Gilead has successfully launched Yeztugo, the successor to its blockbuster Biktarvy. Gilead expects Yeztugo sales to reach $100 million in Q4, even though it was only approved by the FDA on June 18 last year. Even weak sales of the oncology franchise in Q3 didn't prevent Gilead's EBIT margin from reaching a three-year high of 45.2%.
Gilead Sciences, Inc. (GILD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Gilead Sciences, Inc. (GILD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Here's Why Gilead Sciences (GILD) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Gilead Sciences (GILD) Stock Declines While Market Improves: Some Information for Investors
Gilead Sciences (GILD) concluded the recent trading session at $118.3, signifying a -2.71% move from its prior day's close.
3 Cash-Flow Machines Investors May Want Heading Into 2026
Of the host of financial metrics investors might consider when deciding whether to buy shares of a target company, cash flow is among the most important. Operating cash flow is a reflection of how a firm actually functions on a day-to-day basis and demonstrates the company's ability to bring in money from sales or other sources and to adequately pay salaries, taxes, and other expenses.
Why Gilead Sciences (GILD) Dipped More Than Broader Market Today
In the latest trading session, Gilead Sciences (GILD) closed at $123.18, marking a -1.38% move from the previous day.
GILD Exercises Option to License Assembly Bio's Herpes Programs
Gilead exercises its option to license ASMB's HSV programs for developing long-acting candidates, ABI-1179 & ABI-5366, for recurrent genital herpes.
Will GILD's Strong HIV Portfolio Reap Rewards in 2026?
GILD???s HIV franchise gains momentum as twice-yearly PrEP Yeztugo wins FDA approval and late-stage data back a new single-tablet regimen.
Gilead Sciences (GILD) Increases Despite Market Slip: Here's What You Need to Know
Gilead Sciences (GILD) closed the most recent trading day at $121.36, moving +2.17% from the previous trading session.
GILD's Bictegravir and Lenacapavir Regimen for HIV Meets Primary Goal
Gilead said its once-daily bictegravir/lenacapavir tablet met non-inferiority vs Biktarvy in phase III ARTISTRY-2, paving the way for filings.
